<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn></journal-meta><article-meta><article-id pub-id-type="pmid">1616863</article-id><article-id pub-id-type="pmc">1977775</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A phase I study of regional 5-fluorouracil and systemic folinic acid for patients with colorectal liver metastases.</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Anderson</surname><given-names>J. H.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Kerr</surname><given-names>D. J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cooke</surname><given-names>T. G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McArdle</surname><given-names>C. S.</given-names></name></contrib></contrib-group><aff>University Department of Surgery, Royal Infirmary, Glasgow, UK.</aff><pub-date pub-type="ppub"><month>6</month><year>1992</year></pub-date><volume>65</volume><issue>6</issue><fpage>913</fpage><lpage>915</lpage><abstract><p>A phase I study was undertaken in order to establish the maximum tolerated dose of intra-hepatic arterial 5-fluorouracil (5-FU) when given in combination with systemic folinic acid. Patients with colorectal liver metastases (n = 10) received escalating doses of 5-FU as a 24 h infusion with a fixed dose (400 mg m-2) of intravenous folinic acid once per week. Dose limiting toxicity (WHO grade greater than 2) was encountered at 2 g m-2 5-FU. Principal adverse effects were diarrhoea, vomiting and oral ulceration. The recommended dose for phase II studies is 1.5 g m-2 week-1 24 h 5-FU regional infusion with 400 mg m-2 week-1 intravenous folinic acid.</p></abstract></article-meta></front><body><supplementary-material content-type="scanned-pages"><graphic xlink:href="brjcancer00070-0129.tif" xlink:title="scanned-page" xlink:role="913" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00070-0130.tif" xlink:title="scanned-page" xlink:role="914" mimetype="image" mime-subtype="tiff"/><graphic xlink:href="brjcancer00070-0131.tif" xlink:title="scanned-page" xlink:role="915" mimetype="image" mime-subtype="tiff"/></supplementary-material></body></article>

